Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors

 Abstract

Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentially bypass imatinib resistance in preclinical models of GIST.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
eLocation ID
e24452
doi
10.4161/onci.24452
Type
Author's View
 Metrics
 Cite This Article
 Permissions
Creative Commons License Permissions
 Reprints
Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors